Statement Of Changes In Equity [Abstract]

OSE Immunotherapeutics - Filing #5980970

Concept	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	As at 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	As at 2024-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31
Statement of changes in equity [abstract]
Statement of changes in equity [line items]
Equity	—	17 577 EUR	—	—	—	77 743 EUR	—	4 388 EUR	293,000 EUR	448,000 EUR	—	63 811 EUR	—	—	22 975 EUR	—	57 282 EUR	—	—	76 643 EUR	—	4 330 EUR	309,000 EUR	408,000 EUR	32 658 EUR	35 890 EUR	65 611 EUR	549,000 EUR	3 705 EUR	220,000 EUR
Changes in equity [abstract]
Comprehensive income [abstract]
Profit (loss)	—	—	37 445 EUR	—	—	—	—	—	—	—	37 445 EUR	—	—	23 003 EUR	—	23 003 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Other comprehensive income	—	—	—	—	—	—	—	—	—	—	20,000 EUR	—	—	86,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Comprehensive income	- EUR	—	37 410 EUR	- EUR	- EUR	—	15,000 EUR	—	—	—	37 425 EUR	—	- EUR	23 089 EUR	—	23 012 EUR	—	- EUR	77,000 EUR	—	- EUR	—	—	—	—	—	—	—	—	—
Increase (decrease) through treasury share transactions, equity	40,000 EUR	—	207,000 EUR	—	—	—	—	—	—	—	167,000 EUR	—	141,000 EUR	15,000 EUR	—	126,000 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Increase (decrease) through share-based payment transactions, equity	—	—	2 088 EUR	—	—	—	—	—	—	—	2 088 EUR	—	—	1 746 EUR	—	1 746 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—